PMID- 30135326
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20211204
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 41
IP  - 11
DP  - 2018 Nov 1
TI  - Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by 
      Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome 
      Activation.
PG  - 1638-1644
LID - 10.1248/bpb.b18-00132 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is increasingly prevalent and 
      represents a growing challenge in terms of prevention and treatment. The purpose 
      of this study is to investigate the protective effects of ginsenoside Rg1 (Rg1), 
      an active ingredient of a natural medicine, and further clarify its protective 
      mechanisms, in a mouse model of NAFLD induced by a high-fat diet. Rg1 
      significantly reduced liver weight, serum alanine aminotransferase (ALT), 
      aspartate aminotransferase (AST), triglyceride (TG), liver free fatty acids 
      (FFAs) and malondialdehyde (MDA) levels, and increased superoxide dismutase (SOD) 
      activity. Rg1 also upregulated the expression of peroxisome 
      proliferator-activated receptor-alpha (PPARalpha), which stimulated fatty acid beta 
      oxidation and promoted the metabolism of FFAs and TG. It also suppressed the 
      expression of CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP), 
      cysteine-containing aspartate-specific proteases 12 (Caspase 12), and 
      glucose-regulated protein78 (GRP78), which reduced endoplasmic reticulum (ER) 
      stress. Furthermore, Rg1 alleviated liver inflammation by inhibiting the 
      activation of nucleotide binding oligomerization domain (NOD)-like receptor 
      family pyrin domain-containing 3 (NLRP3) and thus reduced the production of 
      inflammatory cytokines, such as interleukin 1-beta (IL-1beta) and interleukin 18 
      (IL-18). These results suggested that Rg1 may protect against NAFLD, through 
      regulation of lipid peroxidation, ER stress and inflammasome activation.
FAU - Xu, Yashu
AU  - Xu Y
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
FAU - Yang, Cheng
AU  - Yang C
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
FAU - Zhang, Shujun
AU  - Zhang S
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
FAU - Li, Jiajun
AU  - Li J
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
FAU - Xiao, Qing
AU  - Xiao Q
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
FAU - Huang, Wenxiang
AU  - Huang W
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Chongqing 
      Medical University.
LA  - eng
PT  - Journal Article
DEP - 20180821
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antioxidants)
RN  - 0 (CCAAT-Enhancer-Binding Proteins)
RN  - 0 (CEBPA protein, mouse)
RN  - 0 (Cytokines)
RN  - 0 (Endoplasmic Reticulum Chaperone BiP)
RN  - 0 (Ginsenosides)
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Hspa5 protein, mouse)
RN  - 0 (Inflammasomes)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Nlrp3 protein, mouse)
RN  - 0 (PPAR alpha)
RN  - EC 3.4.22.- (Caspase 12)
RN  - PJ788634QY (ginsenoside Rg1)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism/pharmacology/therapeutic use
MH  - CCAAT-Enhancer-Binding Proteins/metabolism
MH  - Caspase 12/metabolism
MH  - Cytokines/metabolism
MH  - Diet, High-Fat/adverse effects
MH  - Disease Models, Animal
MH  - Endoplasmic Reticulum Chaperone BiP
MH  - Endoplasmic Reticulum Stress/*drug effects
MH  - Female
MH  - Ginsenosides/*pharmacology/therapeutic use
MH  - Heat-Shock Proteins/metabolism
MH  - Inflammasomes/*metabolism
MH  - Inflammation/etiology/metabolism/prevention & control
MH  - Lipid Metabolism/drug effects
MH  - Lipid Peroxidation/*drug effects
MH  - Liver/*drug effects/enzymology/metabolism
MH  - Mice, Inbred C57BL
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
MH  - Non-alcoholic Fatty Liver Disease/etiology/*metabolism/prevention & control
MH  - PPAR alpha/metabolism
MH  - Panax/*chemistry
MH  - Phytotherapy
OTO - NOTNLM
OT  - endoplasmic reticulum stress
OT  - ginsenoside Rg1
OT  - lipid peroxidation
OT  - non-alcoholic fatty liver disease
EDAT- 2018/08/24 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/08/24 06:00
PHST- 2018/08/24 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2018/08/24 06:00 [entrez]
AID - 10.1248/bpb.b18-00132 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2018 Nov 1;41(11):1638-1644. doi: 10.1248/bpb.b18-00132. Epub 
      2018 Aug 21.